Extended Data Fig. 1: The trial design and outcomes of OOC-001.

a, Trial flow diagram. b, Representative pre- and post-treatment intraoral photographs, H&E staining, and MRI images for MPR and noMPR patients. Scale bar = 50 μm. c, The changes and proportional statistics of TNM staging after treatment for lymph nodes in different patients. d, Scatter plot depicts the pathological response and radiographic response of the primary tumor after neoadjuvant treatment in the same patient (left), and the radiographic response of the primary tumor and lymph node metastasis in the same patient after neoadjuvant treatment (right). e, Pathological response of the primary tumor in patients treated with different cycles during neoadjuvant therapy (left), radiographic response of the primary tumor in patients treated with different cycles during neoadjuvant therapy (middle), and all remission include primary tumor and lymph node metastasis in patients treated with different cycles during neoadjuvant therapy (right). Sample sizes by treatment cycle: 2 cycles (n = 25), 3 cycles (n = 22), 4 cycles (n = 4). f, The rates of MPR for patients after 2 cycles, 3 cycles, and 4 cycles of treatment, as well as the rates of Grade 1-2 adverse events and Grade 3-4 adverse events. g, Survival curves for patients in this clinical trial at the 24-month follow-up. h, Disease-free survival (DFS) and OS curves for patients in this clinical trial at the 24-month follow-up. Boxes represent interquartile range (IQR, 25th–75th percentile), horizontal lines within boxes indicate medians, whiskers extend to 1.5×IQR.